Result of Annual General Meeting

RNS Number : 2125D

Hemogenyx Pharmaceuticals PLC

25 June 2021

 

25 June 2021

Hemogenyx Pharmaceuticals plc 

("Hemogenyx Pharmaceuticals" or the "Company")

Result of Annual General Meeting

Hemogenyx Pharmaceuticals plc is pleased to announce that, at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed. The numbers of votes for each resolution are presented below.

AGM Voting Results

Ordinary Resolutions	Votes for	% of votes cast for	Votes Against	% of votes cast against	Total votes cast	Total votes cast as % of ISC (1)	Votes with-held (2)
1. To adopt the 2020 Annual Report and Accounts​	126,557,317	99.87%	168,193	0.13%	126,725,510	12.93%	289,150
2. To approve the Directors' Remuneration Policy​	125,619,330	99.07%	1,177,033	0.93%	126,796,363	12.94%	218,297
3. To approve the Directors' Remuneration Report​	125,638,477	99.07%	1,177,033	0.93%	126,815,510	12.94%	199,150
4. To reappoint the Company's auditor​	126,528,170	99.87%	168,193	0.13%	126,696,363	12.93%	318,297
5. To authorise the Audit Committee to determine the auditor's remuneration​	126,356,107	99.72%	350,256	0.28%	126,706,363	12.93%	308,297
6. To re-elect Sir Marc Feldmann as a director of the Company	125,895,121	99.28%	911,242	0.72%	126,806,363	12.94%	208,297
7. To authorise the Directors to allot equity securities​	125,663,209	99.11%	1,133,154	0.89%	126,796,363	12.94%	218,297
Special Resolutions	Votes for	% of votes cast for	Votes against	% of votes cast against	Total votes cast	Total votes cast as % of ISC (1)	Votes with-held (2)
8. To disapply pre-emption provisions​	123,047,368	97.04%	3,748,995	2.96%	126,796,363	12.94%	218,297
9. To adopt new Articles of Association​	125,663,209	99.27%	923,154	0.73%	126,586,363	12.92%	428,297
10. To adopt new Articles of Association​	126,014,268	99.36%	811,242	0.64%	126,825,510	12.94%	189,150

(1)  The Company's issued share capital ("ISC") on 23 June 2021, being the date on which members had to be entered in the register of members of the Company in order to be entitled to attend and vote at the meeting, was 979,749,321 ordinary shares.

(2)  A 'vote withheld' in respect of any resolution is not a vote in law and is not counted in the calculation of the proportion of the votes for and against it.

Enquiries:

Hemogenyx Pharmaceuticals plc	https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder	[e-mail]
Peter Redmond, Director	[e-mail]
SP Angel Corporate Finance LLP	Tel: [phone]
Matthew Johnson, Vadim Alexandre, Adam Cowl
Peterhouse Capital Limited	Tel: [phone]
Lucy Williams, Duncan Vasey, Charles Goodfellow

 

END

 

 

RAGDKPBNQBKDDAB